Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Increasing Carfentanil Positivity in Clinical Urine Specimens from 2024 to 2025

SOFT-THIAFT 2026

Joint meeting between Society of Forensic Toxicologists and The International Association of Forensic Toxicologists

Chicago, IL, Sep 19-24, 2026

Oral presentation: Increasing Carfentanil Positivity in Clinical Urine Specimens from 2024 to 2025 

(abstract can be found on page 456 in the abstract book: link above)

Authors: Bland AA, Neifeld JR, Meli TM, Yeomans NR, Pacana AL, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

Publication
Prevalence of Novel Psychoactive Substances in Selected Clinical Urine Specimens Submitted for Drug Monitoring
Conference Presentation
The Prevalence of Other Additive Novel Psychoactive Substances and Polydrug Positivity in Clinical Urine Specimens
Audio Podcast
Alternative Specimen Collection Options
Conference Presentation
Carfentanil and Other Fentanyl Analog Prevalence in Clinical Urine Specimens Analyzed Using a High-Throughput Novel Psychoactive Substances Testing Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.